Avant Diagnostics
Avant Diagnostics: Pioneering large panel biomarker screening for early, pre-symptomatic cancer detection.
Founded
2008Avant Diagnostics: Pioneering large panel biomarker screening for early, pre-symptomatic cancer detection.
Avant Diagnostics, Inc. (OTCQB: AVDX) is a medical diagnostic technology company founded with the mission to revolutionize early cancer detection through advanced biomarker screening. The company's core focus is on developing and commercializing large panel biomarker tests, particularly for the early, pre-symptomatic detection of ovarian cancer. Avant Diagnostics aims to provide healthcare professionals with cutting-edge tools to improve patient outcomes by identifying cancers at their most treatable stages.
Notable affiliated individuals include key researchers and scientists in the field of oncology and diagnostics. The company has garnered attention from investors interested in innovative healthcare solutions. Avant Diagnostics' significant achievements include progressing towards FDA approval for its ovarian cancer detection test, which has the potential to significantly impact early cancer diagnosis and treatment. Through its pioneering technology, Avant Diagnostics is poised to make a substantial impact on the medical diagnostics industry and patient care.
Companies similar to Avant Diagnostics include Acuamark Diagnostics, AOA Dx, Promiss Diagnostics and Stage I Diagnostics.
Avant Diagnostics was founded in 2008.
Avant Diagnostics' headquarters is located in Scottsdale, AZ, US.
Avant Diagnostics' most recent funding round was for $1.2M (USD) in June 2018.
As of Jun 12, 2018, Avant Diagnostics has disclosed funding of $1.3M (USD). Undisclosed round amounts are excluded.
Avant Diagnostics has 11 employees as of Feb 5, 2024.
Stage I Diagnostics
